Martine A. Rothblatt Reports 4.0% Stake in United Therapeutics (Schedule 13G/A)

Overview

On November 4, 2026, Martine A. Rothblatt filed Amendment No. 8 to Schedule 13G with the SEC regarding holdings in United Therapeutics Corporation (CIK: 0001082554).

Key Filing Highlights

• Date of Event: September 30, 2026
• Aggregate Beneficial Ownership: 1,725,721 shares of Common Stock
• Percent of Class: 4.0%
• Threshold Status: Item 5 indicates that the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities.

Voting and Dispositive Power Breakdown

• Sole Voting Power: 755,805 shares
• Shared Voting Power: 969,916 shares
• Sole Dispositive Power: 755,805 shares
• Shared Dispositive Power: 969,916 shares

Footnote & Holding Context

Beneficial ownership includes:

• Currently exercisable options to purchase 706,650 shares held directly by Dr. Rothblatt.
• Currently exercisable options to purchase 328,410 shares held by a family trust with shared investment and voting power.
• Shares held across various family trusts, spouse's accounts, and charitable organizations over which Dr. Rothblatt or her spouse exercise sole or shared voting and dispositive power.

Market Significance

This filing documents that Dr. Rothblatt's beneficial ownership has fallen to 4.0%, moving below the 5% threshold requiring Schedule 13D/13G ongoing reporting.